相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Using Artificial Intelligence to Detect, Classify, and Objectively Score Severity of Rodent Cardiomyopathy
Debra A. Tokarz et al.
TOXICOLOGIC PATHOLOGY (2021)
Deep Learning in Toxicologic Pathology: A New Approach to Evaluate Rodent Retinal Atrophy
Maria Cristina De Vera Mudry et al.
TOXICOLOGIC PATHOLOGY (2021)
Developing a Qualification and Verification Strategy for Digital Tissue Image Analysis in Toxicological Pathology
Aleksandra Zuraw et al.
TOXICOLOGIC PATHOLOGY (2021)
Quantitative neurotoxicology: Potential role of artificial intelligence/deep learning approach
Anshul Srivastava et al.
JOURNAL OF APPLIED TOXICOLOGY (2021)
Ovarian Toxicity Assessment in Histopathological Images Using Deep Learning
Fangyao Hu et al.
TOXICOLOGIC PATHOLOGY (2020)
Improved protein structure prediction using potentials from deep learning
Andrew W. Senior et al.
NATURE (2020)
Quantifying drug-induced structural toxicity in hepatocytes and cardiomyocytes derived from hiPSCs using a deep learning method
Mahnaz Maddah et al.
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS (2020)
Personalized predictions of patient outcomes during and after hospitalization using artificial intelligence
C. Beau Hilton et al.
NPJ DIGITAL MEDICINE (2020)
Drug-induced skin toxicity: gaps in preclinical testing cascade as opportunities for complex in vitro models and assays
Rhiannon N. Hardwick et al.
LAB ON A CHIP (2020)
Pharmacokinetic Study of Osimertinib in Cancer Patients with Mild or Moderate Hepatic Impairment
Enrique Grande et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2019)
Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors
Ariella B. Hanker et al.
CANCER DISCOVERY (2019)
Management of toxicity to isoform α-specific PI3K inhibitors
S. E. Nunnery et al.
ANNALS OF ONCOLOGY (2019)
Ruxolitinib binding to human serum albumin: bioinformatics, biochemical and functional characterization in JAK2V617F+ cell models
Elisabetta De Marinis et al.
SCIENTIFIC REPORTS (2019)
A survey on Image Data Augmentation for Deep Learning
Connor Shorten et al.
JOURNAL OF BIG DATA (2019)
Digital analysis yields more reliable and accurate measures of dermal and epidermal thickness in histologically processed specimens compared to traditional methods
Sergey Y. Turin et al.
EXPERIMENTAL DERMATOLOGY (2018)
Development of deep neural network for individualized hepatobiliary toxicity prediction after liver SBRT
Bulat Ibragimov et al.
MEDICAL PHYSICS (2018)
Tox_(R)CNN: Deep learning-based nuclei profiling tool for drug toxicity screening
Daniel Jimenez-Carretero et al.
PLOS COMPUTATIONAL BIOLOGY (2018)
Clinical Pharmacokinetics and Pharmacodynamics of Afatinib
Sven Wind et al.
CLINICAL PHARMACOKINETICS (2017)
Sea Buckthorn (Hippophae rhamnoides L.) Oil Improves Atopic Dermatitis-Like Skin Lesions via Inhibition of NF-κB and STAT1 Activation
Dian-Dong Hou et al.
SKIN PHARMACOLOGY AND PHYSIOLOGY (2017)
Distinct Angiogenic Changes during Carcinogenesis Defined by Novel Label-Free Dark-Field Imaging in a Hamster Cheek Pouch Model
Fangyao Hu et al.
CANCER RESEARCH (2017)
Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients
Kenji Tamura et al.
CANCER SCIENCE (2016)
The Next Era: Deep Learning in Pharmaceutical Research
Sean Ekins
PHARMACEUTICAL RESEARCH (2016)
In Vitro Skin Models and Their Predictability in Defining Normal and Disease Biology, Pharmacology, and Toxicity
Dimitry M. Danilenko et al.
TOXICOLOGIC PATHOLOGY (2016)
Dark field optical imaging reveals vascular changes in an inducible hamster cheek pouch model during carcinogenesis
Fangyao Hu et al.
BIOMEDICAL OPTICS EXPRESS (2016)
Severe lmatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications
Sook Ryun Park et al.
CANCER RESEARCH AND TREATMENT (2016)
The c-Met Tyrosine Kinase Inhibitor JNJ-38877605 Causes Renal Toxicity through Species-Specific Insoluble Metabolite Formation
Martijn P. Lolkema et al.
CLINICAL CANCER RESEARCH (2015)
Cutaneous adverse effects of targeted therapies Part II: Inhibitors of intracellular molecular signaling pathways
James B. Macdonald et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2015)
Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies
Yook-Hwan Noh et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors
Mark A. Dickson et al.
INVESTIGATIONAL NEW DRUGS (2015)
Skin Tumorigenesis Stimulated by Raf Inhibitors Relies Upon Raf Functions That Are Dependent and Independent of ERK
Eszter Doma et al.
CANCER RESEARCH (2013)
Cutaneous toxicities of BRAF inhibitors: Clinical and pathological challenges and call to action
Mario Mandala et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2013)
1α,25-Dihydroxyvitamin-D3-3-Bromoacetate Regulates AKT/mTOR Signaling Cascades: A Therapeutic Agent for Psoriasis
Ananya Datta Mitra et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management
I. Manousaridis et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Principles for Valid Histopathologic Scoring in Research
K. N. Gibson-Corley et al.
VETERINARY PATHOLOGY (2013)
EGFR regulation of epidermal barrier function
Quynh T. Tran et al.
PHYSIOLOGICAL GENOMICS (2012)
Prediction of Oral Pharmacokinetics of cMet Kinase Inhibitors in Humans: Physiologically Based Pharmacokinetic Model Versus Traditional One-Compartment Model
Shinji Yamazaki et al.
DRUG METABOLISM AND DISPOSITION (2011)
IL-23-Mediated Psoriasis-Like Epidermal Hyperplasia Is Dependent on IL-17A
Heather L. Rizzo et al.
JOURNAL OF IMMUNOLOGY (2011)
Preclinical pharmacokinetics of the novel PI3K inhibitor GDC-0941 and prediction of its pharmacokinetics and efficacy in human
Laurent Salphati et al.
XENOBIOTICA (2011)
Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans
Adam D. Shilling et al.
DRUG METABOLISM AND DISPOSITION (2010)
Beyond wavy hairs - The epidermal growth factor receptor and its ligands in skin biology and pathology
Marlon R. Schneider et al.
AMERICAN JOURNAL OF PATHOLOGY (2008)
Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors
Hironobu Minami et al.
CANCER SCIENCE (2008)
The epidermal growth factor receptor system in skin repair and inflammation
Saveria Pastore et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2008)
Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption
Alon Scope et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Influence of skin color in the development of erlotinib-induced rash: A report from the SERIES clinic
S. E. Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Hand-foot and stump syndrome to sorafenib
Susan E. Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Mechanisms of cutaneous toxicities to EGFR inhibitors
Mario E. Lacouture
NATURE REVIEWS CANCER (2006)
Assessment of the human epidermis model SkinEthic RHE for in vitro skin corrosion testing of chemicals according to new OECD TG 431
H Kandárová et al.
TOXICOLOGY IN VITRO (2006)
The EpiDerm test protocol for the upcoming ECVAM validation study on in vitro skin irritation tests -: An assessment of the performance of the optimised test
H Kandárová et al.
ATLA-ALTERNATIVES TO LABORATORY ANIMALS (2005)
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients
B Peng et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
分享论文
